Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Eye on 9 million plus EV sales by 2027, government, auto companies gear up to tap India’s potential
- New India-UAE bilateral treaty to ensure continuity of investment protection: Centre
- Budget 2025: Agri industry calls for policy reforms to boost sustainability and rural growth
- Primus Partners Survey Reveals Optimistic Outlook for Viksit Bharat: Indians Express Confidence and 33 Experts Chart the Roadmap for Amrit Kaal
